By Colin Kellaher

Novartis AG and Incyte Corp. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of the blood-cancer drug Jakavi for the treatment of acute and chronic graft-versus-host disease.

The companies said the recommendation covers the treatment of patients ages 12 and up who have inadequate response to corticosteroids or other systemic therapies.

The European Commission, which generally follows the CHMP's advice, would now review the recommendation, with a decision expected within about two months.

The companies said Jakavi, if approved, would be the first JAK1/2 inhibitor available in Europe for patients with graft-versus-host disease, a condition in which donated bone marrow or stem cells attack a transplant recipient's organs.

Under a long-running collaboration, Wilmington, Del., biopharmaceutical company Incyte markets the drug as Jakafi in the U.S., while Switzerland's Novartis markets it as Jakavi outside the U.S.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 25, 2022 09:07 ET (13:07 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Novartis.